Searched for
BIOLOGIC DRUG ITOLIZUMAB
Biocon starts clinical study to evaluate efficacy of ItolizumabThis is a phase two randomised, double-blind, parallel-group, placebo and active-controlled (adalimumab), two treatment period study to eva...- Biocon Biologics says clinical study for drug Itolizumab initiated in India after approval from DCGIBiocon's partner US-based Equillium Inc has expanded its 'EQUALISE' study in Systemic Lupus Erythematosus (SLE) and Lupus Nephritis for Ito...
- Biocon Biologics gets licence from Adagio Therapeutics for antibody treatment of COVID-19"ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses, is in global clinical development ...
- Biocon Biologics provided 7,000 doses of Itolizumab in AprilThe company does not look at Covid-19 related drugs as a business opportunity; it expects higher growth this fiscal year on the back of new...
- Billion dollar target for biologics biz by FY22 unrealistic, but we would soon return to high growth trajectory: Kiran Mazumdar Shaw“There is a marginal decline in biosimilar segment but we expect to see the business pick up in Q1 of FY22.”
- Biocon Q1 results: Net profit declines 28% to Rs 149 croreThe Bengaluru-headquartered biopharma company’s revenue was up 14% at Rs 1,690 crore during the quarter.
- Biocon defends limited trial patients for Itolizumab nod, says followed science of "highest order"The company is marketing the drug as a replacement to Roche Pharma’s Tocilizumab (originally approved for rheumatoid arthritis) that is cur...
- Biocon to take on Roche Pharma with its psoriasis drug to treat moderate to severe Covid patientsThe company is marketing the drug as a replacement to Roche’s tocilizumab (originally approved for rheumatoid arthritis) that is currently ...
- Biocon jumps 10%, hits 52-week high as DCGI approves use of Itolizumab on Covid-19 patientsThe drug, which is also used to cure the skin disease psoriasis, was cleared by the Drug Controller General of India (DCGI) for usage in In...
- Biocon to launch drug for COVID-19 patients; priced at Rs 8,000 per vialNew Delhi, Jul 13 () Biotechnology major Biocon on Monday said it will launch biologic drug Itolizumab for the treatment of moderate to sev...
- Biocon’s biosimilar for treating Covid-19: Patients responded positively, says Kiran Mazumdar-ShawThe Drug Controller General of India (DGCI) has permitted the Bengaluru-headquartered drug maker to market Itolizumab (ALZUMab) injection 2...
- Biocon gets DCGI nod to use Itolizumab in moderate to severe Covid-19 patientsBiocon said the approval is based on the results from the successful conclusion of a randomized, controlled clinical trial at multiple hosp...
- Biosimilar drugs can help us reach $1 billion target soon: Christiane Hamacher, CEO, Biocon BiologicsIt is all about reaching our $1billion revenue target by FY22 and to reach 5 million patients by end of 2022, says Christiane Hamacher.
- Biocon says use of Itolizumab in COVID-19 treatment encouragingBiocon has witnessed encouraging results in the use of its novel biologic Itolizumab for treating some Covid-19 related conditions, the pha...
- Looking at 'repurposing' drugs: BioconWe are working to repurpose our novel monoclonal antibody Itolizumab (used in psoriasis) to treat complications caused by Covid-19 infectio...
- Small molecule, API biz to be growth drivers for company: Kiran Mazumdar Shaw, Biocon"We have focused on creating key growth drivers and have structured the company along those growth drivers," says Kiran Mazumdar Shaw.
- Biocon seeking partners to develop, market psoriasis drugBiotechnology major Biocon today said it is looking for partners to develop and market its novel biologic drug Itolizumab
- Biocon to launch psoriasis drug novel biologic in JulyThe company had received marketing authorisation for Itolizumab from the Drugs Controller General of India (DCGI) in January, 2013.
- Biocon eyes Rs 100 cr from psoriasis drug in next four yearsThe product would be manufactured and formulated as an infusion drug at Biocon's biopharma manufacturing facility at Biocon Park, Bangalore.
- Biocon gets DCGI approval to market anti-psoriasis drug, Itolizumab"The company has received market authorisation from the DCGI for its novel biologic Itolizumab, for treatment of chronic plaque psoriasis,"...
Load More
